NG CAROLYN 4
4 · BICYCLE THERAPEUTICS plc · Filed May 30, 2019
Insider Transaction Report
Form 4
NG CAROLYN
Director
Transactions
- Conversion
Ordinary Shares
2019-05-28+206,767→ 1,621,168 total(indirect: By Vertex Global Healthcare Fund I PTE. LTD) - Conversion
Series B1 Preferred Shares
2019-05-28−1,272,733→ 0 total(indirect: By Vertex Global Healthcare Fund I PTE. LTD)→ Ordinary Shares (1,272,733 underlying) - Conversion
Ordinary Shares
2019-05-28+1,272,733→ 1,272,733 total(indirect: By Vertex Global Healthcare Fund I PTE. LTD) - Purchase
Ordinary Shares
2019-05-27$14.00/sh+571,429$8,000,006→ 571,429 total(indirect: By Vertex Venture Management PTE LTD.) - Exercise of In-Money
Ordinary Shares
2019-05-28+141,668→ 1,414,401 total(indirect: By Vertex Global Healthcare Fund I PTE. LTD) - Exercise of In-Money
Series B1 Preferred Shares Warrants
2019-05-28−141,668→ 0 total(indirect: By Vertex Global Healthcare Fund I PTE. LTD)→ Ordinary Shares (141,668 underlying) - Conversion
Series B2 Preferred Shares
2019-05-28−206,767→ 0 total(indirect: By Vertex Global Healthcare Fund I PTE. LTD)→ Ordinary Shares (206,767 underlying)
Footnotes (2)
- [F1]Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.
- [F2]Upon conversion of all of the Series B1 Preferred Shares into Ordinary Shares in connection with the Issuer's initial public offering, the Warrants became exercisable for Ordinary Shares. The Warrants had an exercise price of a nominal value per share and were exercised immediately prior to completion of the Issuer's initial public offering.